F S&P 500
5,065.00 +17.50 (+0.35%) F Dow Jones
38,576.00 +108.00 (+0.28%) F Nasdaq
17,414.50 +64.50 (+0.37%) E-mini Russell 2000 Index Futur
1,980.50 -2.10 (-0.11%) Petróleo
81.06 -0.84 (-1.03%) Oro
2,326.00 -20.40 (-0.87%)
Lexicon Pharmaceuticals, Inc. (LXRX)
Antes de la apertura del mercado:
Lexicon Pharmaceuticals, Inc.
2445 Technology Forest Boulevard
11th Floor
The Woodlands, TX 77381
United States
281 863 3000
https://www.lexpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 285
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Lonnel Coats | CEO & Director | 1.14M | N/D | 1965 |
| Mr. Jeffrey L. Wade J.D. | President & CFO | 752.05k | N/D | 1965 |
| Mr. Brian T. Crum | Senior VP, General Counsel & Secretary | 596.48k | N/D | 1973 |
| Dr. Alan J. Main Ph.D. | Executive Vice President of Innovation & Chemical Sciences | 576.96k | N/D | 1954 |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior VP & Chief Medical Officer | 652.48k | N/D | 1965 |
| Ms. Kristen L. Alexander | Vice President of Finance & Accounting | N/D | N/D | 1968 |
| Ms. Lisa M. DeFrancesco | Head of Investor Relations & Corporate Strategy | N/D | N/D | 1980 |
| Mr. Dixon Terry | Vice President of Compliance | N/D | N/D | N/D |
| Ms. Carrie Siragusa | Vice President of Marketing | N/D | N/D | N/D |
| Ms. Desiree Gendron | Vice President of Sales & Training | N/D | N/D | N/D |
Descripción
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Lexicon Pharmaceuticals, Inc. a partir del 1 de abril de 2024 es 10. Las puntuaciones principales son Auditoría: 8; Junta: 10; Derechos del accionista: 7; Compensación: 10.
